MENU
+Compare
RLMD
Stock ticker: NASDAQ
AS OF
May 9 closing price
Price
$0.42
Change
+$0.06 (+16.67%)
Capitalization
13.92M

RLMD Relmada Therapeutics Forecast, Technical & Fundamental Analysis

Relmada Therapeutics Inc is a clinical-stage biotechnology company... Show more

RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RLMD with price predictions
May 09, 2025

RLMD in upward trend: 10-day moving average broke above 50-day moving average on April 22, 2025

The 10-day moving average for RLMD crossed bullishly above the 50-day moving average on April 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

RLMD moved above its 50-day moving average on April 30, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where RLMD advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 205 cases where RLMD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for RLMD moved out of overbought territory on April 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RLMD as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RLMD turned negative on April 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RLMD broke above its upper Bollinger Band on April 22, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.334) is normal, around the industry mean (14.691). P/E Ratio (0.000) is within average values for comparable stocks, (62.420). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.860). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.625).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RLMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RLMD is expected to report earnings to fall 40.85% to -36 cents per share on May 12

Relmada Therapeutics RLMD Stock Earnings Reports
Q1'25
Est.
$-0.37
Q4'24
Beat
by $0.09
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.24
Q1'24
Beat
by $0.26
The last earnings report on March 27 showed earnings per share of -62 cents, beating the estimate of -70 cents. With 613.29K shares outstanding, the current market capitalization sits at 13.92M.
A.I. Advisor
published General Information

General Information

a clinical-stage biotechnology company, which engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2222 Ponce de Leon Boulevard
Phone
+1 786 629-1376
Employees
20
Web
https://www.relmada.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA298.2613.44
+4.72%
Tesla
GME27.540.76
+2.84%
GameStop Corp
AAPL198.531.04
+0.53%
Apple
SPY564.34-0.72
-0.13%
SPDR® S&P 500® ETF
BTC.X102970.850000-270.609380
-0.26%
Bitcoin cryptocurrency

RLMD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with ENTO. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then ENTO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLMD
1D Price
Change %
RLMD100%
+15.47%
ENTO - RLMD
35%
Loosely correlated
+5.09%
ARGNF - RLMD
31%
Poorly correlated
-21.00%
ATXS - RLMD
27%
Poorly correlated
-3.86%
TPST - RLMD
26%
Poorly correlated
-5.26%
CYTK - RLMD
26%
Poorly correlated
-2.42%
More